03309 C-MER EYE
- 3.160
- 0.0000.00%
C-MER EYE News
希瑪眼科：年度報告 2023
The associated corporation of Hima Ophthalmology (03309.HK) was granted an additional 400,000 shares of common stock by Lam Shun Chao, worth approximately HK$800,000
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, 2021, Lam Shun-chao increased his OTC share holdings of $Hima Ophthalmology (03309.HK) $ with an average price of HK$2.0 per share by 400,000 shares, worth approximately HK$800,000. After the increase in holdings, Lin Shunchao's latest shareholding number of shares in the associated corporation was 900,000 shares, with a good position ratio of 10.00%. Photo Source: Stock Exchange Shareholding Disclosure
Lam Shun Chao sold 2.3 million common shares of the associated corporation of Hima Ophthalmology (03309.HK) worth approximately HK$14.352 million off the market
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Lam Shun-chao sold 2.3 million common shares of the allied corporation Health Hope Pharma Limited worth about HK$14.352 million on March 11 at an average price of HK$6.24 per share. After the sale, Lin Shunchao's latest shareholding in the associated corporation was 4.7 million shares, and the good position ratio dropped from 70.00% to 47.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange
The associated corporation of Hima Ophthalmology (03309.HK) obtained an additional shareholding of 6.993 million shares of common stock from Lam Shun Chao, worth about HK$6.993 million
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Lam Shun-chao increased his OTC share holdings of $Hima Ophthalmology (03309.HK) $ on March 1 by an average price of HK$1.0 per share, to a value of about HK$6.993 million. After the increase in holdings, Lin Shunchao's latest shareholding number of shares in the associated corporation was 7 million shares, with a good position ratio of 70.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, the majority shareholder (holding 5% of the shares
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Hima Ophthalmology (3309.HK): Mainland dental performance is impressive, and the Greater Bay Area business is worth looking forward to
Event: On March 26, 2024, Hima Ophthalmology released its 2023 report. The company achieved revenue of HK$1,924 million (+11.09%) and gross profit of HK$619 million (+38.25%), EDITDA
Xima Ophthalmology (03309) announced annual results. Profit attributable to shareholders was HK$61.98 million, turning a year-on-year loss into a profit
According to the Zhitong Finance App, Xima Ophthalmology (03309) announced annual results for the year ended December 31, 2023, with revenue of HK$1,924 million, up 11.1% year on year; the company's equity holders should have accounted for the profit of HK$61.98 million during the year, while the same period in 2022 recorded a loss of HK$21.875 million and a profit of HK4.94 cents per share. According to the announcement, total revenue in 2023 was HK$1,924 million, a slight increase of 11.1% over 2022, due to core medical service revenue in 2023 (including provision of ophthalmology services, provision of dental and other medical services, and sales
C-MER EYE: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
C-mer Eye Care Holdings Foresses HK$65 Million in 2023 Profit
C-mer Eye Care Holdings (HKG:3309) expects a profit attributable to the equity holders of the Company in the range of HK$60.0 million to HK$65.0 million for the year ended Dec. 31, 2023, compared with
Changes in Hong Kong stocks | Hima Ophthalmology (03309) is expected to increase by more than 5%. Net profit last year was not less than HK$60 million and turned a year-on-year loss into profit
Hima Ophthalmology (03309) rose more than 5%. As of press release, it rose 5.35% to HK$3.15, with a turnover of HK$5.166,600.
Selected Announcements | Li Ning Responds to Privatization Rumors: I don't know the reason for the stock price change; BOSS Direct Hire had a net profit of 1,099 billion yuan last year, an increase of more than 9 times over the previous year
Luoyang Molybdenum Industry: Net profit of 8.25 billion yuan in 2023, up 35.98% year on year; China People's Insurance Group: total premium income of the subsidiary in the first 2 months was 159.849 billion yuan; Shandong Xinhua Pharmaceutical Co., Ltd. obtained a registration certificate for ibuprofen sustained-release capsules.
Hima Ophthalmology (03309.HK) Profit: Expected net profit of HK$60 million to HK$65 million in 2023
Gelonghui March 12 | Xima Ophthalmology (03309.HK) announced that according to the currently available unaudited financial data for the year ended 31 December 2023, the company is expected to turn a loss into a profit, bringing the profit attributable to the company's equity holders to HK$60 million to HK$65 million, while a loss attributable to equity holders was recorded at HK$21.9 million for the year ended 31 December 2022. Profit attributable to the company's equity holders is expected to increase, mainly due to the increase in revenue from medical services by more than 30% from HK$1.43 billion in FY2022 to FY2023
希瑪眼科：正面盈利預告
Hima Ophthalmology (03309.HK) plans to hold a board meeting on March 26 to approve annual results
Glonghui, March 8, 丨 Hima Ophthalmology (03309.HK) announced that the board of directors meeting will be held on March 26, 2024 (Tuesday) to approve (among other things) the publication of the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider proposals for payment of a final dividend (if any).
C-MER EYE: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Hima Ophthalmology (03309) rose more than 6%, Shenzhen Aikangjian Hospital was included in the “Greater Bay Area Pilot Program for Elderly Health Care Vouchers”
Hima Ophthalmology (03309) rose by more than 6% and rose 6.53% at press time to report at HK$3.1 million, with a turnover of HK$3.05 million.
C-MER Dental Hospital Added to Greater Bay Area Elder Care Scheme
C-MER Eye Care's (HKG:3309) Shenzhen CKJ Stomatological Hospital has been added to the Elderly Health Care Voucher Greater Bay Area Pilot Scheme, making the facility one of seven institutions and the
Hima Ophthalmology (03309): Shenzhen Aikangjian Hospital was included in the “Greater Bay Area Pilot Program for Elderly Health Care Vouchers”
Hima Ophthalmology (03309) issued an announcement as the Hong Kong Special Administrative Region Government (Hong Kong Government, China) 2023...
Xima Ophthalmology (03309.HK) signed a strategic cooperation agreement with the Shenzhen Luohu District Government for the construction of the Luohu Port Hong Kong-style Port Hospital
Gelonghui, Feb. 19 | Hima Ophthalmology (03309.HK) announced that as part of the cross-border medical collaboration under the Hong Kong Special Administrative Region Government's 2023 Policy Address, the Hong Kong Government announced on February 19, 2024 that Shenzhen Aikangjian Dental Hospital has been included as one of the seven medical institutions under the Greater Bay Area Pilot Program for the Elderly. It is also the only dental hospital in the pilot program to cover the provision of dental services under the Guangdong-Hong Kong-Macao Greater Bay Area Health Care Voucher. Approximately 1.7 million eligible elderly people in Hong Kong are expected to benefit from the pilot scheme. In the process of selecting medical institutions in the Greater Bay Area for the pilot program, the Hong Kong Government
C-MER Eye Care Holdings Repurchases 808,000 Shares
C-MER Eye Care Holdings (HKG:3309) bought back 808,000 shares on the market during the week of Nov. 13 to Nov. 17 for HK$3 million at between HK$3.68 and HK$3.81 apiece, a Friday filing said. The eye
Analysis
Price Target
No Data
